Christoph Boesecke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christoph Boesecke has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Jürgen Kurt Rockstroh
Department of Medicine I University Hospital Bonn Bonn Germany
11 shared publications - Ulrich Spengler
Department of Internal Medicine I, University of Bonn, Bonn, Germany
5 shared publications - Jacob Nattermann
Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany
4 shared publications - Sven Breitschwerdt
Department of Medicine I University Hospital Bonn Bonn Germany
4 shared publications Axel Baumgarten
Zfi-Zentrum für Infektiologie, Berlin, Germany
3 shared publications- Benjamin Krämer
Freiburg Institute for Advanced Studies University of Freiburg Freiburg Germany
3 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (11) , 107925
Outcomes for persons with triple-class resistant HIV and a history of virologic failure
- 13 July 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (11) , 107925
Open AccessOutcomes for persons with triple-class resistant HIV and a history of virologic failure
- Open Access
- 24 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (9) , 1-16
Glecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection
Introduction In a phase 3b study, glecaprevir/pibrentasvir (G/P) for 8 weeks was well tolerated and effective in treatment-naive adults with acute hepatitis C virus (HCV) infection. Here we analyze the efficacy and safety of G/P in adults with acute HCV infection with a history of prior HCV infection. Methods Participants with acute HCV were stratified by presence of prior HCV infection. Efficacy was assessed in the intention-to-treat population (ITT; all patients receiving ≥ 1 G/P dose) and modified ITT virologic failure population, which excluded non-virologic failures (mITT-VF). Safety (adverse events [AEs] and laboratory values) was assessed, as well as viral kinetics. Results Among 286 participants, 52 (18.2%) had ≥ 1 prior HCV infection and 234 (81.8%) did not. High-risk characteristics in those with prior infection versus those without: human immunodeficiency virus (HIV) coinfection, 92.3% versus 40.2%; unprotected male–male sexual activity, 78.8% versus 63.7%; and current/recent injection drug use, 23.1% versus 12.4%, respectively. In the ITT, SVR12 was 98.1% (95% confidence interval [CI] 89.9–99.7) in those with a prior infection and 95.7% (95% CI 92.3–97.7) in those without. There were no virologic failures (SVR12 = 100% in the mITT-VF). Rates of serious AEs (5.8% versus 3.0%) and treatment-related AEs (17.3% versus 15.4%) were similar in those with or without prior HCV infection. Conclusions Individuals with acute HCV infection with a history of prior HCV infection can be successfully treated with G/P. Risk of reinfection in high-risk populations, such as high-risk sexual activity or injection drug use, highlights the need for ongoing testing for reinfection along with subsequent treatment. Trial Registration ClinicalTrials.gov identifier: NCT04903626.
- 24 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (9) , 1-16
Open AccessGlecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection
Introduction In a phase 3b study, glecaprevir/pibrentasvir (G/P) for 8 weeks was well tolerated and effective in treatment-naive adults with acute hepatitis C virus (HCV) infection. Here we analyze the efficacy and safety of G/P in adults with acute HCV infection with a history of prior HCV infection. Methods Participants with acute HCV were stratified by presence of prior HCV infection. Efficacy was assessed in the intention-to-treat population (ITT; all patients receiving ≥ 1 G/P dose) and modified ITT virologic failure population, which excluded non-virologic failures (mITT-VF). Safety (adverse events [AEs] and laboratory values) was assessed, as well as viral kinetics. Results Among 286 participants, 52 (18.2%) had ≥ 1 prior HCV infection and 234 (81.8%) did not. High-risk characteristics in those with prior infection versus those without: human immunodeficiency virus (HIV) coinfection, 92.3% versus 40.2%; unprotected male–male sexual activity, 78.8% versus 63.7%; and current/recent injection drug use, 23.1% versus 12.4%, respectively. In the ITT, SVR12 was 98.1% (95% confidence interval [CI] 89.9–99.7) in those with a prior infection and 95.7% (95% CI 92.3–97.7) in those without. There were no virologic failures (SVR12 = 100% in the mITT-VF). Rates of serious AEs (5.8% versus 3.0%) and treatment-related AEs (17.3% versus 15.4%) were similar in those with or without prior HCV infection. Conclusions Individuals with acute HCV infection with a history of prior HCV infection can be successfully treated with G/P. Risk of reinfection in high-risk populations, such as high-risk sexual activity or injection drug use, highlights the need for ongoing testing for reinfection along with subsequent treatment. Trial Registration ClinicalTrials.gov identifier: NCT04903626.
- Open Access
- 1 June 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2977-2980
Paucisymptomatic opisthorchiasis in a non-endemic country: a neglected differential diagnosis?
Case presentation: We report a case of opisthorchiasis in a 71-year-old woman with intermittent upper abdominal pain, whose cause had remained unclear for a long time. She grew up in Kazakhstan and moved to Germany more than 30 years ago. After positive serological testing for Opisthorchis during a recent visit to her home country, she presented at our clinic for further evaluation. Stool examination confirmed the presence of Opisthorchis eggs. The symptoms quickly resolved after treatment with praziquantel. Abdominal sonography revealed adenomyomatosis of the gallbladder fundus and multiple gallbladder polyps, most likely a consequence of chronic inflammation caused by the parasite. Sonographic surveillance was recommended with regard to a potentially increased risk of cholangiocarcinoma. Discussion and conclusions: No certified serological test for opisthorchiasis is available in Germany and molecular or antigen-based tests for this infection are also largely unavailable. Diagnosis therefore has to rely on stool microscopy which requires the examination of multiple samples to ensure adequate sensitivity. Diagnosis is further complicated as symptoms are often nonspecific and liver flukes are usually not among the initial differential diagnoses. Missing the diagnosis, however, carries the risk of serious complications. Global travel and migration as well as recent autochthonous cases in the European Union underscore the need for increased vigilance for opisthorchiasis even in non-endemic areas.
- 1 June 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2977-2980
Open AccessPaucisymptomatic opisthorchiasis in a non-endemic country: a neglected differential diagnosis?
Case presentation: We report a case of opisthorchiasis in a 71-year-old woman with intermittent upper abdominal pain, whose cause had remained unclear for a long time. She grew up in Kazakhstan and moved to Germany more than 30 years ago. After positive serological testing for Opisthorchis during a recent visit to her home country, she presented at our clinic for further evaluation. Stool examination confirmed the presence of Opisthorchis eggs. The symptoms quickly resolved after treatment with praziquantel. Abdominal sonography revealed adenomyomatosis of the gallbladder fundus and multiple gallbladder polyps, most likely a consequence of chronic inflammation caused by the parasite. Sonographic surveillance was recommended with regard to a potentially increased risk of cholangiocarcinoma. Discussion and conclusions: No certified serological test for opisthorchiasis is available in Germany and molecular or antigen-based tests for this infection are also largely unavailable. Diagnosis therefore has to rely on stool microscopy which requires the examination of multiple samples to ensure adequate sensitivity. Diagnosis is further complicated as symptoms are often nonspecific and liver flukes are usually not among the initial differential diagnoses. Missing the diagnosis, however, carries the risk of serious complications. Global travel and migration as well as recent autochthonous cases in the European Union underscore the need for increased vigilance for opisthorchiasis even in non-endemic areas.
- Open Access
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Both Smallpox and Mpox Vaccine Reduce Mpox Disease Severity and Symptoms
Background: Data on the impact of completing 2 doses of the modified vaccinia Ankara vaccine and/or smallpox vaccination in childhood on Mpox disease severity remain limited. During the last months of 2024, Germany faced a second Mpox wave, providing the opportunity to study the impact of different vaccine regimens including smallpox vaccination. Methods: Retrospective analysis of all cases diagnosed at 17 participating German centers 2022–2024. Cases were grouped according to smallpox vaccine history: “unvaccinated,” “incomplete” (vaccinations only during childhood and/or only one MVA BN), “complete” (2 MVA BN > 1 month prior to Mpox diagnosis). Disease severity was assessed by a 7-item Mpox Severity Scoring System (MPOX-SSS). Results: Of 273 Mpox infections, 42% occurred in men who have sex with men (MSM) living with HIV (median CD4 724 cells/µl, 91% <50 HIV-RNA copies/ml), 58% occurred in MSM without HIV, most of them using HIV PrEP. Median age was 38 years (IQR 30–44). Vaccinated individuals demonstrated lower MPOX-SSS scores compared to unvaccinated individuals (mean score 5.46 vs 7.15, P < .001). Vaccinated individuals also had less fever (23% vs 59%, P < .001), headaches/chills (29% vs 54%, P < .001), and swollen lymph nodes (38% vs 56%, P = .02). Conclusions: Both incomplete and complete vaccine courses including smallpox vaccination during childhood appear to reduce Mpox disease severity and symptoms. In settings of limited vaccine resources, unvaccinated risk groups should be prioritized.
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open AccessBoth Smallpox and Mpox Vaccine Reduce Mpox Disease Severity and Symptoms
Background: Data on the impact of completing 2 doses of the modified vaccinia Ankara vaccine and/or smallpox vaccination in childhood on Mpox disease severity remain limited. During the last months of 2024, Germany faced a second Mpox wave, providing the opportunity to study the impact of different vaccine regimens including smallpox vaccination. Methods: Retrospective analysis of all cases diagnosed at 17 participating German centers 2022–2024. Cases were grouped according to smallpox vaccine history: “unvaccinated,” “incomplete” (vaccinations only during childhood and/or only one MVA BN), “complete” (2 MVA BN > 1 month prior to Mpox diagnosis). Disease severity was assessed by a 7-item Mpox Severity Scoring System (MPOX-SSS). Results: Of 273 Mpox infections, 42% occurred in men who have sex with men (MSM) living with HIV (median CD4 724 cells/µl, 91% <50 HIV-RNA copies/ml), 58% occurred in MSM without HIV, most of them using HIV PrEP. Median age was 38 years (IQR 30–44). Vaccinated individuals demonstrated lower MPOX-SSS scores compared to unvaccinated individuals (mean score 5.46 vs 7.15, P < .001). Vaccinated individuals also had less fever (23% vs 59%, P < .001), headaches/chills (29% vs 54%, P < .001), and swollen lymph nodes (38% vs 56%, P = .02). Conclusions: Both incomplete and complete vaccine courses including smallpox vaccination during childhood appear to reduce Mpox disease severity and symptoms. In settings of limited vaccine resources, unvaccinated risk groups should be prioritized.
- Open Access
- 24 November 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (4) , 702-712
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C
- 24 November 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (4) , 702-712
Open AccessA single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C
- Open Access
- 16 June 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (8) , 1317-1320
Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?
- 16 June 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (8) , 1317-1320
Open AccessUse of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?
- Open Access
- 19 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13613
Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures
This longitudinal study examined how active gastrointestinal (GI) cancer types affect immune responses to SARS-CoV-2, focusing on the ability to neutralize the Omicron variants. Patients with GI cancer (n = 168) were categorized into those with hepatocellular carcinoma, hepatic metastatic GI cancer, non-hepatic metastatic GI cancer, and two control groups of patients with and without underlying liver diseases. Humoral and cellular immune responses were evaluated before and after Omicron antigen exposures. In the pre-Omicron era, humoral SARS-CoV-2 immunity decreased after three antigen contacts without further antigen exposure. While Omicron neutralization was significantly lower than wildtype neutralization (p < 0.01), Omicron infections were yet mild to moderate. Additional Omicron exposures improved IgG levels (p < 0.01) and Omicron neutralization (p < 0.01). However, this effect was significantly less intense in patients with active GI cancer, particularly in patients with pancreaticobiliary neoplasms (PBN; p = 0.04), with underlying immunodeficiency (p = 0.05), and/or under conventional chemotherapy (p = 0.05). Pre-Omicron SARS-CoV-2 immunity prevented severe clinical courses of infections with Omicron variants in patients with GI cancer. However, in patients with PBN, with underlying immunodeficiency, and/or under conventional chemotherapy initial contacts with Omicron antigens triggered only reduced immune responses. Thus, subgroups could be identified for whom booster vaccinations are of special clinical significance.
- 19 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13613
Open AccessLongitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures
This longitudinal study examined how active gastrointestinal (GI) cancer types affect immune responses to SARS-CoV-2, focusing on the ability to neutralize the Omicron variants. Patients with GI cancer (n = 168) were categorized into those with hepatocellular carcinoma, hepatic metastatic GI cancer, non-hepatic metastatic GI cancer, and two control groups of patients with and without underlying liver diseases. Humoral and cellular immune responses were evaluated before and after Omicron antigen exposures. In the pre-Omicron era, humoral SARS-CoV-2 immunity decreased after three antigen contacts without further antigen exposure. While Omicron neutralization was significantly lower than wildtype neutralization (p < 0.01), Omicron infections were yet mild to moderate. Additional Omicron exposures improved IgG levels (p < 0.01) and Omicron neutralization (p < 0.01). However, this effect was significantly less intense in patients with active GI cancer, particularly in patients with pancreaticobiliary neoplasms (PBN; p = 0.04), with underlying immunodeficiency (p = 0.05), and/or under conventional chemotherapy (p = 0.05). Pre-Omicron SARS-CoV-2 immunity prevented severe clinical courses of infections with Omicron variants in patients with GI cancer. However, in patients with PBN, with underlying immunodeficiency, and/or under conventional chemotherapy initial contacts with Omicron antigens triggered only reduced immune responses. Thus, subgroups could be identified for whom booster vaccinations are of special clinical significance.
- Open Access
HIV Care in Ukrainian Migrants in Two European Countries: All the Same?
Introduction: War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two infectious disease departments in Bonn, Germany, and Szczecin, Poland. Methods: This is a retrospective study on 161 people living with HIV (PLWH) refugees from Ukraine seeking care in Bonn (n = 30) and Szczecin (n = 131) between April 2022 and May 2023. Demographic, virologic, immunologic, and coinfection data were analyzed. Results: The majority of the studied individuals were female: 64% (n = 84) in Szczecin and 60% (n = 18) in Bonn. The main HIV transmission mode was heterosexual sex in 73.5% (n = 114). All were on combined antiretroviral therapy (cART) on arrival, primarily on the TLD regimen (TDF/3TC/DTG) (68.4%, n = 106). In Germany, cART was most frequently switched to BIC/TAF/FTC in 83.4% (n = 25); in Poland, the most common combination was TDF/FTC + DTG (58%, n = 76). A prevalence of replicating hepatitis C was in 11.7% (n = 15), and that for chronic hepatitis B (HBV) was in 4.7% (n = 4). History of past tuberculosis was reported in 16.9% (n = 14, Poland, and n = 7, Germany). Follow-up after 6 months showed immunological reconstitution with a mean increase of CD4+ of 10 (IQR: −69.5–120.5) cells/µL in Poland and 51.5 (IQR: −22.5–135.5) cells/µL in Germany; p = 0.04. Virologic suppression (<40 HIV-RNA/mL) was high in care entry (n = 62; 98%) for Poland, and n = 26 (92.6%) for Germany, and suppression was achieved in the majority of patients in the 6-month control (89.7% in Poland vs. 95.7% in Germany). Conclusions: Health challenges posed by war migration extend beyond HIV to coinfections as HBV, HCV, and tuberculosis give an indication for a broader search for coinfections, often less common in the new country.
Open AccessHIV Care in Ukrainian Migrants in Two European Countries: All the Same?
Introduction: War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two infectious disease departments in Bonn, Germany, and Szczecin, Poland. Methods: This is a retrospective study on 161 people living with HIV (PLWH) refugees from Ukraine seeking care in Bonn (n = 30) and Szczecin (n = 131) between April 2022 and May 2023. Demographic, virologic, immunologic, and coinfection data were analyzed. Results: The majority of the studied individuals were female: 64% (n = 84) in Szczecin and 60% (n = 18) in Bonn. The main HIV transmission mode was heterosexual sex in 73.5% (n = 114). All were on combined antiretroviral therapy (cART) on arrival, primarily on the TLD regimen (TDF/3TC/DTG) (68.4%, n = 106). In Germany, cART was most frequently switched to BIC/TAF/FTC in 83.4% (n = 25); in Poland, the most common combination was TDF/FTC + DTG (58%, n = 76). A prevalence of replicating hepatitis C was in 11.7% (n = 15), and that for chronic hepatitis B (HBV) was in 4.7% (n = 4). History of past tuberculosis was reported in 16.9% (n = 14, Poland, and n = 7, Germany). Follow-up after 6 months showed immunological reconstitution with a mean increase of CD4+ of 10 (IQR: −69.5–120.5) cells/µL in Poland and 51.5 (IQR: −22.5–135.5) cells/µL in Germany; p = 0.04. Virologic suppression (<40 HIV-RNA/mL) was high in care entry (n = 62; 98%) for Poland, and n = 26 (92.6%) for Germany, and suppression was achieved in the majority of patients in the 6-month control (89.7% in Poland vs. 95.7% in Germany). Conclusions: Health challenges posed by war migration extend beyond HIV to coinfections as HBV, HCV, and tuberculosis give an indication for a broader search for coinfections, often less common in the new country.
- Open Access
- 27 May 2024
- Published by Wiley in HIV Medicine
- Vol. 25 (8) , 976-989
Still trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021
Objectives: To identify sexual/sex‐associated risk factors for hepatitis C transmission among men who have sex with men (MSM) and visualise behavioural trajectories from 2019 to 2021.Methods: We linked a behavioural survey to a hepatitis C cohort study (NoCo), established in 2019 across six German HIV/hepatitis C virus (HCV) treatment centres, and performed a case–control analysis. Cases were MSM with recent HCV infection, and controls were matched for HIV status (model 1) or proportions of sexual partners with HIV (model 2). We conducted conditional univariable and multivariable regression analyses.Results: In all, 197 cases and 314 controls completed the baseline questionnaire and could be matched with clinical data. For regression models, we restricted cases to those with HCV diagnosed since 2018 (N = 100). Factors independently associated with case status included sex‐associated rectal bleeding, shared fisting lubricant, anal douching, chemsex, intravenous and intracavernosal injections, with population‐attributable fractions of 88% (model 1) and 85% (model 2). These factors remained stable over time among cases, while sexual partner numbers and group sex decreased during COVID‐19 measures.Conclusions: Sexual/sex‐associated practices leading to blood exposure are key factors in HCV transmission in MSM. Public health interventions should emphasize the importance of blood safety in sexual encounters. Micro‐elimination efforts were temporarily aided by reduced opportunities for sexual encounters during the COVID‐19 pandemic.
- 27 May 2024
- Published by Wiley in HIV Medicine
- Vol. 25 (8) , 976-989
Open AccessStill trouble with bleeding: Risk factors for HCV transmission in men who have sex with men and behavioural trajectories from 2019 to 2021
Objectives: To identify sexual/sex‐associated risk factors for hepatitis C transmission among men who have sex with men (MSM) and visualise behavioural trajectories from 2019 to 2021.Methods: We linked a behavioural survey to a hepatitis C cohort study (NoCo), established in 2019 across six German HIV/hepatitis C virus (HCV) treatment centres, and performed a case–control analysis. Cases were MSM with recent HCV infection, and controls were matched for HIV status (model 1) or proportions of sexual partners with HIV (model 2). We conducted conditional univariable and multivariable regression analyses.Results: In all, 197 cases and 314 controls completed the baseline questionnaire and could be matched with clinical data. For regression models, we restricted cases to those with HCV diagnosed since 2018 (N = 100). Factors independently associated with case status included sex‐associated rectal bleeding, shared fisting lubricant, anal douching, chemsex, intravenous and intracavernosal injections, with population‐attributable fractions of 88% (model 1) and 85% (model 2). These factors remained stable over time among cases, while sexual partner numbers and group sex decreased during COVID‐19 measures.Conclusions: Sexual/sex‐associated practices leading to blood exposure are key factors in HCV transmission in MSM. Public health interventions should emphasize the importance of blood safety in sexual encounters. Micro‐elimination efforts were temporarily aided by reduced opportunities for sexual encounters during the COVID‐19 pandemic.
- Open Access
- 20 July 2023
- Published by Springer Nature in Infection
- Vol. 51 (5) , 1223-1239
Prevalence, characteristics and challenges of late HIV diagnosis in Germany: an expert narrative review
Purpose: We aimed to review the landscape of late HIV diagnosis in Germany and discuss persisting and emerging barriers to earlier diagnosis alongside potential solutions. Methods: We searched PubMed for studies informing the prevalence, trends, and factors associated with late HIV diagnosis in Germany. Author opinions were considered alongside relevant data. Results: In Germany, older individuals, heterosexuals, and migrants living with HIV are more likely to be diagnosed late. The rate of late diagnosis in men who have sex with men (MSM), however, continues to decrease. Indicator conditions less often prompt HIV testing in women and non-MSM. During the COVID-19 pandemic, the absolute number of late diagnoses fell in Germany, but the overall proportion increased, probably reflecting lower HIV testing rates. The Ukraine war and subsequent influx of Ukrainians living with HIV may have substantially increased undiagnosed HIV cases in Germany. Improved indicator testing (based on unbiased assessments of patient risk) and universal testing could help reduce late diagnoses. In patients who receive a late HIV diagnosis, rapid treatment initiation with robust ART regimens, and management and prevention of opportunistic infections, are recommended owing to severely compromised immunity and increased risks of morbidity and mortality. Conclusion: Joint efforts are needed to ensure that UNAIDS 95-95-95 2030 goals are met in Germany. These include greater political will, increased funding of education and testing campaigns (from government institutions and the pharmaceutical industry), continued education about HIV testing by HIV experts, and broad testing support for physicians not routinely involved in HIV care.
- 20 July 2023
- Published by Springer Nature in Infection
- Vol. 51 (5) , 1223-1239
Open AccessPrevalence, characteristics and challenges of late HIV diagnosis in Germany: an expert narrative review
Purpose: We aimed to review the landscape of late HIV diagnosis in Germany and discuss persisting and emerging barriers to earlier diagnosis alongside potential solutions. Methods: We searched PubMed for studies informing the prevalence, trends, and factors associated with late HIV diagnosis in Germany. Author opinions were considered alongside relevant data. Results: In Germany, older individuals, heterosexuals, and migrants living with HIV are more likely to be diagnosed late. The rate of late diagnosis in men who have sex with men (MSM), however, continues to decrease. Indicator conditions less often prompt HIV testing in women and non-MSM. During the COVID-19 pandemic, the absolute number of late diagnoses fell in Germany, but the overall proportion increased, probably reflecting lower HIV testing rates. The Ukraine war and subsequent influx of Ukrainians living with HIV may have substantially increased undiagnosed HIV cases in Germany. Improved indicator testing (based on unbiased assessments of patient risk) and universal testing could help reduce late diagnoses. In patients who receive a late HIV diagnosis, rapid treatment initiation with robust ART regimens, and management and prevention of opportunistic infections, are recommended owing to severely compromised immunity and increased risks of morbidity and mortality. Conclusion: Joint efforts are needed to ensure that UNAIDS 95-95-95 2030 goals are met in Germany. These include greater political will, increased funding of education and testing campaigns (from government institutions and the pharmaceutical industry), continued education about HIV testing by HIV experts, and broad testing support for physicians not routinely involved in HIV care.